Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M

Ionis Pharmaceuticals ( NASDAQ: IONS ) has agreed to sell licensing rights for its experimental blood disorder therapy sapablursen to Japanese pharma Ono Pharmaceutical ( OTCPK:OPHLF ) in a deal worth up to $940M. The RNA-targeted medicine, with the FDA’s Fast Track and orphan drug designations, is.